Introduction
Since histopathology of the bone marrow had not been considered in therapy trials on Ph þ chronic myeloid leukemia (CML), [1] [2] [3] [4] [5] [6] [7] [8] there is a lack of long-term observations of marrow histomorphology on the basis of prospective taking of marrow biopsies during the course of disease. The retrospective reports on the prognostic significance of marrow fibrosis (MF) in CML are controversial, [9] [10] [11] [12] and MF is presumed to correlate with anemia, splenomegaly, blast counts 11 and accelerated phase, 13 factors known to influence survival times. Thus, in the data sets from 1303 patients with Ph þ CML recruited from 14 studies on interferon (IFN)-a treatment in order to evaluate and validate prognostic factors, 'Bone marrow features regarding megakaryocytes as well as fibrosis were not included, since hardly any of that information on participants was available'. 7 Some effects of treatment on the histopathology of bone marrow were reported, especially a regression of MF during hydroxyurea (HU) medication [14] [15] [16] and tyrosine kinase inhibition. [17] [18] [19] Although an antifibrotic effect of IFN-a on fibrosis in other organs, especially in the liver and skin, 20, 21 was repeatedly reported, mainly due to a reduction of procollagen production and an inhibition of proliferation of fibroblasts, 20 the data on the impact of IFN-a on fibrosis in bone marrow during the course of CML and other myeloproliferative disorders are controversial, ranging from prevention of increasing fibrosis or its reversal [22] [23] [24] [25] [26] [27] to a fibrogenic effect. 15, 16, 28 The numbers of patients evaluated in these studies are rather small. To the best of our knowledge, prospective data from randomized-controlled trials on the effect of IFN-a on MF have not yet been presented, and long-term observations during tyrosine kinase inhibition are lacking as yet. The significance of evolving MF during the course of CML has not been clarified in context with the cytogenetic response and the evolution of therapy resistance, and comparisons with treatment regimens on the basis of a random assignment of therapies are lacking at present. The long-term reports on MF in CML were based on bone marrow biopsies (BMBs) collected retrospectively, not considering the reasons why these biopsies had been taken. The retrospective nature may be an important reason for the controversies on the effect of IFN-a on MF in CML, since sequential BMBs are usually taken dependent on the individual response to therapy to detect toxic side effects on bone marrow or acceleration of disease, especially when the patient is suspected of having a MF (dry aspiration).
Therefore, the long-term results on MF from patients recruited in a large therapy trial on CML 29, 30 comparing IFN-a with two chemotherapy regimens on a random basis are reported. The BMBs had been taken prospectively during defined time intervals, regardless of the individual response. They were evaluated by applying an exact approach, and the results were analyzed considering other important variables before and during therapy, particularly the risk score, the type of therapy applied including allografting, the hematologic and cytogenetic response, the onset of therapy resistance, occurrence of additional chromosome aberrations and acceleration of disease.
Material and methods

Patients and therapy groups
The results presented are based on the BMBs available from a total of 400 patients with Ph-or bcr-abl-positive CML recruited in newly diagnosed and not pretreated chronic phase, who were randomized within the German CML study I (Table 1) . [29] [30] [31] These patients did not differ from the remaining 113 Ph þ patients in the study who lacked sufficient BMBs taking into consideration initial data (age, sex, peripheral blood findings, spleen size), distribution of therapies and course of disease (duration of chronic phase, survival times; not illustrated). Among those patients evaluated for bone marrow histopathology, 110 were randomized to receive IFN-a, 154 to undergo HU treatment and 136 to receive busulfan (Bu; chemotherapy control group). Therapies were applied as published earlier. 29 The bone marrow findings from 30 further patients with healthy bone marrow served as an age-matched control for the fiber content in normal bone marrow.
Evaluations and study design
The histomorphometric results were correlated with clinical, hematologic and cytogenetic data before and during therapy. The analyses were restricted to the values on the days when the BMBs were taken, which were performed at 12-month intervals ( Figure 2 ). The biopsies were taken prospectively, regardless of therapy, remission or progression of disease, to test the significance of bone marrow morphology. Except for the confirmation of toxic side effects and of blast crisis, histopathologic findings were not involved in treatment decisions.
The probability that a BMB was taken during a period with remission or acceleration depended on the duration of these periods, and no systematic differences were detected when comparing the numbers of patients with those expected on the basis of the duration of these periods (not illustrated). Owing to this relation, the analyses were performed considering the dependence on time.
A hematologic remission was defined as described earlier. 29 Up to four BMBs taken during a period with complete hematologic remission were available from 24 patients and up to five biopsies during a partial remission from 137 patients. Data with respect to the percentages of Ph þ cells in bone marrow, estimated on the basis of at least 20 metaphases and evaluated on a day when a BMB had been taken, were available from 347 patients. A total of 100 patients showed up to six histopathologic and cytogenetic evaluations on the same days (median: two evaluations), 13 of them with BMBs during periods with a minimal or minor response (o95% Ph þ metaphases) and nine of them with biopsies during a partial or complete remission of disease (o35% Ph þ metaphases). In all, 59 patients showed additional matching aberrations besides the t(9;22) in at least two metaphases on or before the days when the BMBs were taken.
Therapy resistance was diagnosed in the case of no hematologic remission within 4 months after the start of therapy, of progressive disease in spite of increasing doses of the drug, or when a blast crisis occurred. Blast crisis was diagnosed when blasts and promyelocytes exceeded 30% of peripheral white blood cells or 50% of nucleated cells in the bone marrow. After diagnosis of therapy resistance, the treatment was changed to the other chemotherapy regimen in the chemotherapy groups, and in the IFN group to HU or to BU. A total of 275 patients suffered from therapy resistance during the course of disease, and 83 of these had biopsies taken in the period after the detection of therapy resistance.
In all, 357 patients died during the follow-up evaluation, and 43 patients were still surviving on the day of the last follow-up, 28 after allogeneic bone marrow transplantation and 15 without allografting. When analyzing the survival times during IFN-a and chemotherapy, the follow-up evaluations of the 71 patients who received a bone marrow transplant were censored at the time of transplantation. The time interval from diagnosis to allografting ranged from 0.4 to 8.4 years (mean7 s.d. ¼ 1.971.5; median ¼ 1.4 years). BMBs taken in the period after transplantation were excluded from analysis since they had not been taken prospectively.
Bone marrow biopsies
A total of 878 BMBs were examined for the extent of MF (V MF ), and 876 for the numerical density of megakaryocytes. The numbers of biopsies evaluated per patient ranged from 1 to 8
Figure 1
Illustration of the methods applied to quantify the extent V MF of fibrosis in bone marrow and the numerical density N M of cut megakaryocytes in tissue section. To quantify V MF , the biopsy sections were divided into 250 virtual squares of equal size (b, d; measuring oculars). Each square was examined to see whether or not it covered a marrow region with excessive fiber increase. 32 The extent of fibrosis (V MF ) was quantified by the ratio of squares covering marrow regions with fibrosis (b, d: marked with ' þ '; squares without fibrosis are marked with 'À'). On the left, the bone marrow of a patient with Ph þ CML suffering from advanced MF 4 years after the onset of BU therapy is illustrated (a, b: V MF ¼ 33/ 48 ¼ 0.69). The middle column illustrates the bone marrow of another patient with Ph þ CML showing minimal residual fibrosis during major cytogenetic remission 2 years after start of treatment with interferon-a (c, d: V MF ¼ 2/50 ¼ 0.04). The right column (e) shows the bone marrow of a CML patient with complete reversal of initial MF 1 year after start of HU therapy (e: V MF E0.00). Megakaryocytes were quantified (e, f) by dividing biopsy sections into 50 virtual fields of equal size, projecting a measuring square (measuring ocular) into the middle of each field and counting megakaryocytes intersected through their nucleus (f: megakaryocytes ¼ marked by circles). The PAS reaction was applied (not illustrated). N M was determined by dividing the megakaryocyte count by the marrow area examined. Magnifications: Â 100 (a, c), Â 250 (e); Gomori silver impregnation (a, c: with polarization of light); acrylate (a, e) and paraffin (c) embedding.
(mean7s.d. ¼ 2.171.4; therapy groups: Bu: 2.071.2, total ¼ 270; HU: 2.071.3, total ¼ 311; IFN: 2.471.6, total ¼ 267; median ¼ 2 trephines in all therapy groups) covering follow-up periods during therapy of up to 8 years. The time points at which the BMBs were taken and the number of biopsies per patient and year are illustrated in Figure 2 .
In all, 548 BMBs were embedded in methyl methacrylate, 20 in glycol methacrylate without decalcification and 310 in paraffin after decalcification with ethylene-diamine tetra-acetic acid. A total of 690 biopsies were fixed using alcohol-formol combinations (Hannover method), 150 with varying compositions on a formalin basis and 38 using other fixatives. Sections of 3 mm in thickness were cut and stained by Giemsa, PAS and Gomori silver impregnation.
Morphometric approach
Since the publications reporting a prognostic significance of MF in CML or a 'fibrogenic effect' of IFN-a are based on morphometric quantification of fiber content in bone marrow, 12 whereas the publications not confirming these findings are based on less precise semiquantitative evaluations, 9 MF was proven and quantified by an exact approach to achieve representative and adequate results. A new approach was chosen quantifying the volume ratio V MF of marrow affected by fibrosis that allows estimation of the loss of marrow volume due to fibrosis, a consequence of MF that appeared to be crucial for its prognostic significance. 32 This new approach also turned out to be superior to other morphometric methods considering specificity and practicability and superior to a semiquantitative evaluation considering sensitivity, precision and reproducibility. 32 The principle of this new approach is illustrated in Figure 1 . A ratio V MF 40.15 was considered 'obvious fibrosis', a ratio V MF 40.50 'extensive MF'. 32 The collagen and reticulin fibers were marked applying Gomori silver impregnation. Marrow areas free from bone and artifacts were investigated, measuring 10.974.4 mm 2 with 7.873.1 Â 10 4 marrow cells per biopsy section on average. The time consumption was B20 min per slide. The reproducibility, which was checked by estimating the proportion of variance between individual results of different observers, amounted to 3.0% (measurements from two examiners; n ¼ 100).
The numerical density of cut megakaryocytes N M was measured by dividing a biopsy section into 50 fields of equal size, projecting a measuring square of 1.2 Â 10 À1 mm 2 in area (measuring ocular; Â 1000 magnification) in the middle of each field and counting megakaryocytes intersected through their nucleus, including those megakaryocytes cut by the left or lower margins of squares. Megakaryocytes cut by the right or upper margins of squares were disregarded. The PAS reaction was applied, and marrow areas free from bone and artifacts, measuring 3.872.6 mm 2 on average, were investigated. The principle of measurement is illustrated in Figure 1 .
Statistical analyses
Time-dependent mean values of the parameter V MF were sequentially calculated on a day-to-day basis by adding the estimated mean increment from day d to d þ 1 to the current mean value V V d at day d based on the values of all patients with valid values up to at least day d þ 1.
To test the effect of therapy on the development of MF in context with other variables, the measured marrow volume with fibrosis V MF was entered as a dependent variable in the stepwise multiple regression analysis allowing for multiple, time-dependent and correlated measurements within each patient by applying the mixed effect regression model. 33 The Cox proportional-hazard regression model was used to test the prognostic significance. The change in the hazard ratio for one unit increase (continual variable) or the occurrence of a Follow-up periods and number of biopsies evaluated: Although the time points at which the BMBs were taken during therapy varied widely between the patients (a), the mean was about one biopsy per patient and year in all therapy groups (b) (survivors with sequential biopsies). However, due to the death of patients or censoring of observations (c) (allografting, loss of follow-up), the total number of biopsies per patient and year continuously decreased during the course of disease (d).
feature (categorical variable) was used to estimate the relative risk of the event (death, therapy resistance). Variables not changing during therapy were handled as time constant, and all others were included as time-dependent covariates, programming polygons on the basis of the findings on the days when the BMBs were taken. This procedure was superior to a Cox model with fixed covariates based on selected time points during therapy, since (1) the dynamics of the variables during the course of the disease were taken into consideration, which turned out to be important with respect to the course of disease (end of chronic phase, survival time), and (2) any selection of data and time points was avoided, which was relevant because of the shorter follow-up periods of the patients who died early of CML.
When performing the survival analyses, the results were analyzed to ascertain whether the prognostic significance of the variables differed between the therapy groups (variable-therapy interaction terms). The same procedure was applied when analyzing the prognostic significance with respect to the end of the chronic phase (detection of therapy resistance). Therapy resistance was programmed as a categorical variable showing the value '0' before diagnosis of resistance and '1' afterwards. The end of the chronic phase, that is, the beginning of the accelerated phase, was defined by the day on which a therapy resistance was detected. Since we could not detect any superiority of the Sokal index to the new CML score, the Sokal index was not considered when testing the prognostic significance of variables.
The significance of MF before transplantation with respect to the survival after allografting was analyzed by considering the extent of fibrosis V MF in the last biopsy before transplantation, the time interval t up to the day when this biopsy was taken and the interaction between t and V MF in this biopsy, since (1) the majority of patients who received a bone marrow transplantation had only one biopsy taken before allografting, and (2) the extent of MF correlated with the time interval since diagnosis of disease.
The inflated type I error from univariate analyses was met by considering only probabilities of Po0.0005 as 'significant' (Bonferroni method). Owing to the numerous steps required to perform (backward) stepwise regression analyses, a probability level of change of log likelihood less than or equal to 0.005 was used as an inclusion criterion for parameters entered as independent variables in order to avoid overfitting of the model to the data. The variables entered in the final models were interpreted as 'independent factors'.
Results
Number and time points of follow-up evaluations
Although the time points at which the biopsies were taken varied widely between the patients, the mean number of biopsies per patient was about one per year in all three therapy groups (Figure 2a and b; survivors with sequential biopsies). However, due to the loss of follow-up of patients (death, censoring of follow-up evaluations; Figure 2c ), the total number of biopsies per patient and year continuously decreased during the course of disease (Figure 2d ).
MF before and during therapy
At diagnosis, the fiber content V MF in the bone marrow from the CML patients varied widely from less than 0.01 to more than 0.80 in all three therapy groups (Bu: 0.00-0.91; HU: 0.00-0.88; IFN: 0.00-0.81), and the mean fiber content (B0.14 in all therapy groups) exceeded 30 times the amount of normal bone marrow (Table 1 , regression analysis, Po0.00005).
During the course of CML, the mean V MF increased to 0.30-0.40 five years later (Figure 3b-d) , and the proportion of patients showing an obvious fibrosis (V MF X0.15) changed from 30% before the onset of therapy to 70-100% (Figure 3a) .
Influence of therapy
The factor significantly associated with a deceleration or decrease of MF was a therapy with IFN-a or HU (P ¼ 0.00231, multiple regression; Figure 3 ). The superiority to the BU control group became obvious 1-2 years after the onset of therapy (Figure 3 ), whereas the difference between the HU and IFN-a groups was not significant, although IFN-a appeared to be more Figure 3a and d). The delay of fibrosis during HU or IFN-a medication was independent of all other influences on the development of fibrosis during the course of CML (multiple regression, not illustrated). After crossover of therapies, the patients pretreated with IFN-a showed the slowest progression of fibrosis (not illustrated).
Relation to other variables
Peripheral blood findings (erythrocyte, thrombocyte, leukocyte and differential counts, hemoglobin per liter) and spleen size before the onset of therapy did not enable a prediction of the extent of MF during therapy (multiple regression, not illustrated). A lower amount of fibrosis was detected in the bone marrow from patients achieving a complete hematologic remission (V MF ¼ 0.050-0.100; P ¼ 0.00055, Figure 4a ), but the fiber content of healthy marrow that amounted to V MF ¼ 0.00470.008 (n ¼ 30) was not reached (Po0.00005). The extent of fibrosis was also lower in the bone marrow of patients achieving a cytogenetic response (Figure 4b ). However, this tendency was not significant (regression analysis): the fiber content in the bone marrow of the patients achieving minor or partial response varied significantly, and during complete cytogenetic remission minimal residual fibrosis remained, affecting about 5% of bone marrow, a value significantly exceeding the fiber content of normal (healthy) bone marrow (Figures 1c, d and 4b ; Po0.00005).
The number of megakaryocytes, the initial amount of fibrosis and the squared period of time since the onset of treatment correlated independently with the progression of fibrosis during therapy (Po0.000005). A lack of hematologic response, the occurrence of additional numeric or structural chromosomal changes besides t(9;22) and the detection of therapy resistance also correlated with progressive MF (Po0.000005; univariate regression analyses), but these variables did not allow a prediction of the extent of fibrosis during therapy, particularly during IFN-a application (P40.05; multiple regression).
Relation to therapy resistance
The risk of accelerated phase (therapy resistance) markedly increased by a factor of 14 (hazard ratio; Po0.00005) in the case of evolving or progressive MF, independent of the type of therapy given, whereas the risk of therapy resistance significantly decreased when initial fibrosis reversed (Table 2) . Evolving or progressive MF was the only independent predictive indicator of therapy failure valid for all therapy groups, including allografting (multivariate analyses; Tables 2 and 4 ; Po0.00005), preceding the detection of therapy resistance for about 1-2 years (mean and median time intervals; Figures 3a-d  and 4c ) independent of the type of therapy given. The impact of hematologic remission on the detection of therapy resistance depended on the type of therapy given (no independent prediction of therapy resistance during therapy with IFN-a; Table 2 ).
Significance of MF to the survival time of patients
The development of MF turned out to be an important poor prognostic factor during therapy of CML ( Figure 5) , independent of the type of therapy given and of all other parameters evaluated (Table 3 ; multivariate survival analysis; Po0.00005). The new CML score and the extent of hematologic and cytogenetic remission were further independent factors, whereas the type of therapy applied as well as the detection of accelerated phase on the basis of peripheral blood findings, marrow blast counts and spleen size lost their prognostic significance when MF and cytogenetic remission were taken into account (Table 3 ; multivariate analysis). The prognostic relevance of fibrosis did not depend on the way the cytogenetic response was taken into consideration (time-dependent analysis vs maximum remission).
An independent poor prognostic influence of MF was also observed when analyzing the survival after allografting (n ¼ 71; Figure 4 Extent V MF of MF, relation to remission of disease and detection of therapy resistance: higher extent of V MF correlated with loss of remission and detection of therapy resistance. Patients without any biopsy during a remission phase due to shortness of the time intervals with remission are included in the groups without remission (a, b). The relation to therapy resistance (c) was independent of the type of therapy applied (multivariate analysis, not illustrated, see Table 2 ).
Marrow fibrosis -indicator of therapy failure in CML G Buesche et al 2449 P ¼ 0.0002; Figure 5b ). The prognostic relevance of MF was independent of all the other variables taken into consideration (multivariate analysis; Table 4 ), and it became more obvious the longer the period of time since start of nonmyeloablative therapy (V MF Â time), regardless of the type of therapy applied (IFN-a, chemotherapy).
Discussion
MF during therapy of CML
MF is a complication of CML known for many years. [9] [10] [11] [12] 15, 16, 23, 24, 28, 32, [34] [35] [36] [37] Although it is now considered in some recent trials on imatinib treatment of CM, [17] [18] [19] the data presented are the first enabling an unbiased long-term analysis of the occurrence and significance of MF in CML based on the following four important conditions: (1) a randomized trial with (2) prospective taking of BMBs irrespective of remission or progression of disease, (3) prospective consideration of other important variables during the course of CML and (4) controlled observations throughout a very long period of time. The following conclusions can be drawn on the basis of these long-term data:
First, MF does not seem to be a rare event. It was detected in the bone marrow from about 30% of patients before the onset of treatment, confirming earlier observations, 12, 35, 37 and was a typical complication during the course of CML when therapy lost its efficacy, a novel finding. Second, the marrow volume affected by fibrosis appeared to be one of the most important prognostic variables, independent of all other relevant factors before therapy, confirming earlier retrospective observations. [10] [11] [12] The independence of the prognostic relevance of all other relevant factors during therapy was not shown before. The diagnosis of acceleration, as indicated by the changes in the peripheral blood, spleen size and marrow blast counts, even lost its prognostic significance when the extent and development of MF was taken into account, an observation not known up to now. Third, the prognostic significance of MF could be explained neither by the quantity of CML in marrow (cytogenetic response) nor by the quantity of megakaryocytes, although The reduction of the risk in the case of initial fibrosis (V MF in the first biopsy) was explained by the favorable outcome of the patients whose initial fibrosis reversed during therapy. c Prognostic effect of the hematologic response differed between the therapy groups (Po0.00005). Relative risk ¼ estimated change in the hazard rate; NS ¼ not significant. The follow-up evaluations of patients receiving bone marrow transplant were censored on the day of transplantation. The risk of therapy resistance increased by a factor of 14 when MF occurred or progressed. Table 3 Survival time: prognostic significance of marrow fibrosis in context with other variables
Variables before and during therapy (Cox's proportional hazard regression) Multivariate analysis (340 patients in the final model)
Relative risk Significance
New CML Score (low/high risk) 0.7/1. the correlation of MF with the numerical density of these cells, an observation known for more than 10 years, 11, [34] [35] [36] was confirmed.
Fourth, the prognostic significance of MF was not related to therapy, it was independent of the type of treatment, including allogeneic bone marrow transplantation, a prospective observation not reported before.
The close correlation between the development of fibrosis and poor effectiveness of therapy was not previously verified, and the observation that evolving or progressive fibrosis is an early predictor of therapy failure independent of the type of treatment, including allografting, is novel. All the data of the trial analyzed indicate that MF is induced by the neoplastic hematopoiesis, particularly the megakaryopoiesis, in the case of ineffectiveness of therapy so that it is likely that this relation will also be true for a failure of a therapy with a tyrosine kinase inhibitor, although the short-term results during treatment with imatinib mesylate are very promising. [17] [18] [19] 38 Indeed, we observed some patients suffering from evolving or progressive MF during imatinib treatment correlating with loss of efficacy of this agent. However, the periods of observation during this new therapy concept are still too short for a definitive statement.
Considering the increase of marrow volume affected by fibrosis 1-2 years earlier than indicated by the changes in the peripheral blood, the spleen size or marrow blast counts ( Table 2 , Figures 3 and 5) , monitoring of the marrow volume affected by fibrosis should lead to early detection of evolving therapy failure. The significance of this finding is emphasized by the observation that the detection of accelerated phase by the changes in the peripheral blood, spleen size and marrow blast counts did not provide prognostic information independent of monitoring MF during therapy regardless of which type of treatment was considered, whether IFN-a, chemotherapy or allografting.
These observations cannot be explained by chance (Po0.00005). They may be explained by two important advantageous conditions of the data presented: (1) the fact that the BMBs were taken prospectively regardless of the course of disease, and (2) the precision of the approach performed to quantify MF. 32 It is unlikely that the predictive nature of the fiber content in bone marrow with respect to therapy resistance would have been detected if the BMBs had been taken depending on the clinical course. The significance of an exact monitoring of the extent of fibrosis in bone marrow to uncover this prognostic significance of MF is indicated by the The prognostic significance of variables did not differ between the therapy groups.
b V MF in the last biopsy before transplantation Â time interval since the start of therapy. Relative risk ¼ estimated change in the hazard rate; NS ¼ not significant. Patients were excluded from multivariate analysis if data of any variable included in the model were lacking. After allografting, the risk of death increased by a factor of 13 when MF had evolved or progressed during the therapy period before transplantation.
observation that even a very slight increase in the marrow volume with fibrosis of only 5-10%, a change not detectable by semiquantitative grading, correlated with a marked increase in the relative risk of acceleration and therapy failure by about 100%.
Against the background of these findings, the low correlation of MF with the cytogenetic response and the detection of additional chromosome aberrations are remarkable. A complete cytogenetic remission correlated with a low fiber content in the bone marrow, but was not associated with a normalization of the bone marrow morphology: minimal residual fibrosis (V MF E0.05-0.10) could be detected when performing an exact (morphometric) approach (see Figure 1c and d) .
Different dynamics of fibrosis and of neoplastic hematopoiesis and the rather low number of biopsies during periods with a major cytogenetic response might provide an explanation. The rather low number of metaphases usually not exceeding 50 and the negative influence of fibrosis on the aspirability of marrow cells may be further reasons, particularly when comparing them with the rather large amount of marrow evaluated by the morphometric measurements comprising about 0.8 Â 10 5 cells on average. The low correlation between the cytogenetic response and the extent of fibrosis was also observed by other authors and it appears to be independent of the type of therapy given since it was described not only during IFN-a but also during tyrosine kinase inhibition. 17, 24 Therefore, we do not think that the low correlation is explained by chance, it may be explained by technical reasons. If evaluating larger numbers of bone marrow cells and larger numbers of biopsies and applying molecular genetic techniques directly to marrow trephines, the correlation between cytogenetics and morphology of bone marrow might be significantly better.
Nevertheless, considering that MF is primarily related to progress of disease (therapy resistance, accelerated phase), not to remission (cytogenetic response), whereas the cytogenetic response is related to remission of CML, but not to progression (no reliable prediction of accelerated phase by cytogenetic response), its independence of the prognostic significance with respect to the survival of patients should not be a surprise.
IFN-a and MF
A 'fibrogenic effect' of IFN-a during the course of CML was described. 15, 16, 28 By contrast, our observations revealed a protective effect of IFN-a: a significant delay of fibrosis was detected in the IFN-a-treated patient group, similar to observations from smaller numbers of patients. [22] [23] [24] HU seems to prevent progression of fibrosis for 1.5 years, confirming observations from other laboratories. [14] [15] [16] However, IFN-a appears to be more effective, although the difference from HU was not found to be significant. The superiority of IFN-a or HU to BU medication became obvious 1.5-2 years after the onset of therapy. The antifibrotic influence of HU and IFN-a was more obvious before change of treatment, and it appeared independent of all the other factors correlating with the development of fibrosis. Even after change, that is, crossover of therapies, no inferiority of a pretreatment with IFN-a could be observed.
The increase of the marrow volume with fibrosis 1-2 years after the onset of therapy could not be attributed to a 'fibrogenic effect' of any treatment because a correlation between poor effectiveness of therapy and evolving therapy resistance was observed in all the therapy groups. A restriction to the periods before change of treatment with the exclusion of the periods thereafter, as carried out by the authors reporting on a 'fibrogenic effect' of IFN-a during the course of CML, 15, 16, 28 questions the representativeness of such results since the diagnosis of therapy resistance is disregarded, a factor correlating significantly with evolving MF in our patient sample. The results of our therapy trial indicate that IFN-a prevents progressive fibrosis as long as it is effective, suggesting that evolving fibrosis is induced by progressive CML in the presence of resistance to IFN-a. These findings are in accordance with observations on the effect of IFN-a on liver fibrosis in chronic hepatitis, on skin fibrosis and on MF in hairy cell leukemia, explaining fibrosis by the underlying disease and not by the application of IFN-a, 20, 21, 25, 39 particularly since IFN-a proved to reduce the procollagen production as well as the proliferation of fibroblasts, 20 and since inhibitory effects of this cytokine on megakaryocytes could be observed in the marrow from patients with CML. 40 On the basis of these observations, the loss of prognostic significance of the type of therapy in the multivariate survival analysis is remarkable. This finding indicates that the differences in the prognostic significance of the therapy groups may be explained mainly by the differences in the influence on such variables strongly significant to the survival of patients, particularly the remission or progression of CML in bone marrow. Considering the wide variation of the survival times, ranging from less than 2 to more than 10 years in all three therapy groups, it should not be a surprise that the individual outcome could be predicted only by the individual response to therapy, but not by the type of therapy given.
